Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Hodgkin Disease 9Lymphoma 3Urinary Bladder Neoplasms 1Rhabdoid Tumor 1Neoplasms 1Choroid Plexus Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Transitional Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 15Nivolumab 10avelumab 9atezolizumab 8Gemcitabine 8Cisplatin 8Magnetic Resonance Spectroscopy 6durvalumab 5Specimen Handling 5Docetaxel 5Carboplatin 5Paclitaxel 4Ipilimumab 4tislelizumab 3sacituzumab govitecan 3enfortumab vedotin 3Taxes 3Pemetrexed 3Mitomycin 3eribulin 2erdafitinib 2cabozantinib 2Doxorubicin 2CTLA-4 Antigen 2ALT-803 2zimberelimab 1veliparib 1urelumab 1tazemetostat 1spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Transitional Cell × Vinblastine × Clear all
NCT05137262 2026-02-18

A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
12 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡